Peer Exchange

Diagnosis of Multiple Sclerosis: The McDonald Criteria

Differential Diagnosis of Multiple Sclerosis

MOG-IgG in Multiple Sclerosis

Clinically Isolated Syndrome Versus Multiple Sclerosis

First-Line Therapies for Relapsing Multiple Sclerosis

The Use of Interferon in Multiple Sclerosis

The Use of Glatiramer Acetate in Multiple Sclerosis

Clinical Trials for Cladribine in Multiple Sclerosis

Treating With Cladribine in Multiple Sclerosis

Role of Siponimod in Multiple Sclerosis

Ocrelizumab for the Treatment of Multiple Sclerosis

Role of Ocrelizumab in Europe for Multiple Sclerosis

Role of Diroximel Fumarate in Multiple Sclerosis

Role of Ozanimod in Multiple Sclerosis

Switching Therapies in Multiple Sclerosis

Decision-Making Process for Treating Multiple Sclerosis

The Future of Treating Multiple Sclerosis

Cardiac Amyloidosis Diagnostic Workup

Hypertrophic Cardiomyopathy Historical Prognosis

AL and ATTR Diagnosis: Echo and Noncardiac Biopsy

When Are Heart Biopsies Warranted?

Technetium Pyrophosphate Scan Benefits

Monoclonal Protein Testing and Wild-Type ATTR

Technetium Pyrophosphate Scan Prior to TAVR

AL and ATTR Survival Metrics

Poor Toleration: AL and ATTR Treatment Modification

Cardioversion and Atrial Fibrillation Ablation

Cardiac Amyloidosis: Pacemakers and Defibrillators

Therapy Selection for Congestive Heart Failure

Available ATTR Selective Stabilizers

Cardiomyopathy Management: NSAID Options

TTR Gene Silencers as Cardiomyopathy Treatment

Developing Agents for Cardiac Amyloidosis Management

Overview of Spinal Muscular Atrophy

Phenotypes of Spinal Muscular Atrophy

Newborn Screening for Spinal Muscular Atrophy

Genetic Testing for Spinal Muscular Atrophy

Motor Testing to Assess Patients With SMA

Involvement of Primary Care Physicians in Diagnosing SMA

Pulmonary Care for Patients With Spinal Muscular Atrophy

GI Complications in Patients With Spinal Muscular Atrophy

Multidisciplinary Approach to Treating SMA

Recent Approval of Zolgensma for SMA

STR1VE Trial of Onasemnogene Abeparvovec for SMA

SPR1NT Trial of Onasemnogene Abeparvovec for SMA

Nusinersen for Treatment of SMA

Nusinersen ENDEAR-SHINE and CHERISH-SHINE for SMA

Nusinersen Phase 2 NURTURE Trial for SMA

Risdiplam in Development for SMA

Clinical Trials for Risdiplam for SMA

Final Thoughts on Treating SMA

Overview of Excessive Daytime Sleepiness

Overview of Narcolepsy

Signs and Symptoms of Narcolepsy

Narcolepsy Type 1 and Type 2

Diagnosis of Narcolepsy

Goals of Therapy in Narcolepsy

Nonpharmacologic Therapies for Narcolepsy

Laboratory Testing in Patients with Narcolepsy

Traditional Treatments for Narcolepsy

Pitolisant: Recently FDA Approved for Narcolepsy

Solriamfetol: Recently FDA Approved for Narcolepsy

Deciding Which Drug to Use in Narcolepsy

Insurance Coverage For Drugs to Treat Narcolepsy

Patient Resources Including the Narcolepsy Network

Drugs in Development for Treatment of Narcolepsy

Unmet Needs in the Treatment of Narcolepsy

Advice for Community Physicians Treating Narcolepsy

Referral to a Sleep Specialist to Treat Narcolepsy

Final Thoughts on Treating Narcolepsy

Evolution of MS MRI Guidelines and Alignment With MAGNIMS

Role of Gadolinium and Central Vein Sign in MS Imaging

MS Diagnosis: McDonald Criteria and Gadolinium

Treatment Modifications Based on Inflammatory Activity

Maintaining a Consistent Protocol and Scanner for MS

PML Monitoring and Educating Technicians

Developing International Protocols and Standardized Scanners

Barriers in Use of CMSC Protocol

Impact of Insurance on Scanning and Patient Care

Payer and Patient Education of the Standardized Examination

Final Thoughts on MRI Guidelines and Protocols

Spinal Muscular Atrophy (SMA) Overview

Typical SMA Presentation Upon Diagnosis

Sebastian's Story: Initial SMA Symptoms and Assessment

Spinal Muscular Atrophy Diagnostic Workup

The Importance of Treating SMA Early

Treatment Barriers: Cost, Location, and Delivery

Treating Children and Spinal Tap Risks

Systemic Effect Prevention: Evaluation & Dose Modification

Life During Therapy: Good Days and Bad Days

Multidisciplinary Management and Educational Support

Family Planning for People With SMA

Centers of Excellence and Future Oral Medication

Psychological Effects of SMA on Children and Adults

The Impact of the ENDEAR Trial Regimen

Ongoing Clinical Trials & Managing Patient Expectations

Adopting Neuromuscular Therapies for SMA

Peer Exchange

Global Approaches to the Management of Relapsing Multiple Sclerosis

Management of Cardiac Amyloidosis

Advances in the Treatment of Spinal Muscular Atrophy

Management of Narcolepsy and Excessive Daytime Sleepiness

Updates to the MRI Protocol and Clinical Guidelines for MS: CMSC Working Group

Spinal Muscular Atrophy (SMA): Physician and Patient Management